

Practical Gynecology, 2nd Edition – Chapter 19 References

- *1. **Center for Disease Control and Prevention.** Recommendations to improve preconception health and health care in the United States. MMWR. 2006; 55:1-23. *This paper reviews a set of recommendations for preconception care developed by the CDC/ATSDR aimed at improving the health of women of childbearing age and couples prior to conception. The set of 10 guidelines are based on a review of published research demonstrating conditions that adversely affect pregnancy outcome and the effectiveness of specific interventions.*
2. **DePersio SR, Chen W, Blose D, et al.** Unintended childbearing. MMWR. 1992;41: 933-6.
- *3. **ACOG Technical Bulletin.** Preconception care. Intl J Gynecol Obstet. 1995;50:201-7.
4. **Salganicoff A, Ranji U, Wyn R.** Women and health care: a national profile---key findings from the Kaiser Women's Health Survey. Menlo Park, CA: Kaiser Family Foundation; 2005. Available at <http://www.kff.org/womenshealth/upload/Women-and-Health-Care-A-National-Profile-Key-Findings-from-the-Kaiser-Women-s-Health-Survey.pdf>.
- *5. **Ferrer RL; Sibai BM, Mulrow CD et al.** Management of mild chronic hypertension during pregnancy: a review. Obstet Gynecol. 2000;96(5 Pt 2):849-60. *An excellent review of published research demonstrating the costs and benefits of treatment of mild hypertension during pregnancy. It also provides helpful information about anti-hypertensive medications that should be avoided during pregnancy.*
- *6. **Sibai BM.** Chronic hypertension in pregnancy. Obstet Gynecol. 2002;100:369-77.
7. **Montan S, Ingemarsson I, Marsal K, Sjoberg NO.** Randomized controlled trial of atenolol and pindolol in human pregnancy: effects on fetal haemodynamics. BMJ. 1992; 304: 946-9.
8. **Butters, L, Kennedy S, Rubin PC.** Atenolol in essential hypertension during pregnancy. BMJ. 1990; 301: 587-9.
9. **Lydakis C, Lip GY, Beevers M, Beevers DG.** Atenolol and fetal growth in pregnancies complicated by hypertension. Am J Hypertens. 1999;12:541-7.
- *10. **Shotan A, Widerhorn J, Hurst A, Elkayam U.** Risks of angiotension-converting enzyme inhibition during pregnancy: experimental and clinical evidence, potential mechanisms, and recommendations for use. Am J Med.1994; 96:451-6.
11. **Quan A.** Fetopathy associated with exposure to angiotension converting enzyme inhibitors and angiotensin receptor antagonists. Early Hum Dev. 2006; 82:23-8.

12. **Alwan S, Polifka JE, Friedman JM.** Angiotension II receptor antagonist treatment during pregnancy. *Birth Defects Res A Clin Mol Teratol.* 2005; 73:123-30.
13. **Piertrement C, Malot L, Santerne B et al.** Neonatal acute renal failure secondary to maternal exposure to telmisartan, angiotension II receptor antagonist. *J Perinatol.* 2003;23:254-5.
14. **Serreau R, Luton D, Macher MA, et al.** Developmental toxicity of the angiotension II type I receptor antagonists during human pregnancy: a report of 10 cases. *BJOG.* 2005;112:710-2.
- *15. **National Asthma Education Project: Working Group on Asthma and Pregnancy.** Management of asthma during pregnancy. NIH Publication 93-3279:17-23, 29-33; September 1993.
- *16. **Kitzmilller JL, Gavin LA, Gin GD, et al.** Preconception care of diabetes. *JAMA.* 1991; 265:731-6. *This paper is among important published data demonstrating that tight glycemic control instituted before pregnancy and during early pregnancy is effective in reducing the risk of congenital anomalies in offsprings of women with diabetes.*
- *17. **Willhoite MB, Bennert HW, Palomaki GE, et al.** The impact of preconception counseling on pregnancy outcomes. *Diabetes Care.* 1993;16:450-5.
18. **Janz NK, Herman WH, Becker MP, et al.** Diabetes and pregnancy: factors associated with seeking pre-conception care. *Diabetes Care.* 1995;18:157-64.
19. **Jungers P, Chauveau D, Choukroun G, et al.** Pregnancy in women with impaired renal function. *Clin Nephrol.* 1997;47:281-8.
20. **Callaghan N, Garrett A, Goggin T.** Withdrawal of anticonvulsant drugs in patients free of seizures for two years. *N Eng J Med.* 1988;318:942-6.
- *21. **Delgado-Escueta AV, Janz D.** Consensus guidelines: preconception counseling, management, and care of the pregnant woman with epilepsy. *Neurology.* 1992;42:149-60.
22. **Lopes-Cendes I, Andermann E, Cendes F, et al.** Risk factors for changes in seizure frequency during pregnancy of epileptic women: a cohort study. *AES Proceedings. Epilepsia.* 1992;33:57.
- *23. **Einarson TR, Einarson A.** Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. *Pharmacoepidemiol Drug Saf.* 2005;14:823-7.
24. **Levinson-Castiel R, Merlob P, Linder N, et al.** Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. *Arch Pediatr Adolesc Med.* 2006;160:173-6.

25. **Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al.** Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. *N Engl J Med.* 2006; 354:579-87.
26. **Bonari L, Bennett H, Einarson A, Koren G.** Risks of untreated depression during pregnancy. *Can Fam Physician.* 2004;50:37-9.
27. **Bonari L, Pinto N, Ahn E, et al.** Perinatal risks of untreated depression during pregnancy. *Can J Psychiatry.* 2004;49:726-35.
28. **Burtin P, Taddio A, Ariburnu O, et al.** Safety of metronidazole in pregnancy: a metaanalysis. *Am J Obstet Gynecol.* 1995;172(2 Pt 1): 525-9.
29. **Czeizel AE, Rockenbauer M.** A population based case-control teratologic study of oral metronidazole treatment during pregnancy. *Br J Obstet Gynaecol.* 1998;105:322-7.
- *30. **Workowski, KA, Berman SM.** Sexually transmitted diseases treatment guidelines, 2006. *MMWR Recomm Rep.* 2006 Aug 4;55(RR-11):1-94.
31. **Davis SF, Byers RH Jr, Lindegren ML et al.** Prevalence and incidence of vertically acquired HIV infection in the United States. *JAMA.* 1995; 274:952-5.
- *32. **Connor EM, Sperling RS, Gelber R, et al.** Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. *N Engl J Med.* 1994; 331:1173-80. *An important paper describing a key study demonstrating that Zidovudine administered to women with HIV significantly reduces the risk of maternal to fetal transmission of HIV.*
33. **Kaneda T, Shiraki K, Hirano K, Nagata I.** Detection of maternofetal transfusion by placental alkaline phosphatase levels. *J Pediatr.* 1997;130:730-5.
34. **Lin HH, Kao JH, Hsu HY et al.** Least microtransfusion from mother to fetus in elective cesarean delivery. *Obstet Gynecol.* 1996;87:244-8.
- *35. **United States Public Health Service recommendations for human immunodeficiency virus counseling and voluntary testing for pregnant women.** Centers for Disease Control and Prevention. *MMWR Recomm Rep.* 1995; 44(RR-7):1.
36. **Beasley RP, Lee GC, Roan C-H, et al.** Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. *Lancet.* 1983;2:1099-1102.
37. **Stevens CE, Toy PT, Tong MJ.** Perinatal hepatitis B virus transmission in the United States: prevention by passive-active immunization. *JAMA.* 1985;253:1740-5.
38. **Ohto H, Terazawa S, Sasaki N, et al.** Transmission of hepatitis C virus from mothers to infants. *N Eng J Med.* 1994;330:744-50.

39. **Polywka S.** Low risk of vertical transmission of hepatitis C by breast milk. *Clin Infect Dis.* 1999;29:1327-9.
40. **United States Preventive Services Task Force.** *Guide to Clinical Preventive Services*, 2nd ed. Baltimore: Williams and Wilkins; 1996:269-77, 791-815.
41. **Lee SH, Ewert DP, Frederick PD, Mascola L.** Resurgence of congenital rubella syndrome in the 1990s. *JAMA.* 1992;267:2616-20.
- *42. **Centers for Disease Control and Prevention.** Recommended Adult Immunization Schedule — United States, October 2006 - September 2007. *MMWR* 2006; 55:Q1.
- *43. **Revised ACIP recommendation for avoiding pregnancy after receiving a rubella-containing vaccine.** *MMWR Morb Mortal Wkly Rep* 2001;50:1117.
44. **Shields KE, Galil K, Seward J et al.** Varicella vaccine exposure during pregnancy: data from the first 5 years of the pregnancy registry. *Obstet Gynecol* 2001 Jul; 98(1): 14-9.
45. **Prevention of varicella.** Recommendations of the advisory committee on immunization practices (ACI). *MMWR.* 2007; 56:1.
46. **Stanton CK, Gray RH.** Effects of caffeine consumption on delayed conception. *Am J Epidemiol.* 1995; 142:1322-9.
47. **Cnattingius S, Signorello LB, Anneren G et al.** Caffeine intake and the risk of first-trimester spontaneous abortion. *N Engl J Med.* 2000; 343:1839.
- *48. **Wisborg K, Kesmodel U, Bech BH et al.** Maternal consumption of coffee during pregnancy and stillbirth and infant death in first year of life: prospective study. *BMJ.* 2003; 326:420.
49. **Bracken MB; Triche EW; Belanger K et al.** Association of maternal caffeine consumption with decrements in fetal growth. *Am J Epidemiol.* 2003; 157:456-66.
50. **Colman GJ, Joyce T.** Trends in smoking before, during, and after pregnancy in ten states. *Am J Prev Med.* 2003; 24:29-35.
- *51. **Smoking and Reproductive Health.** ACOG Technical Bulletin. 1993;180:1-5.
52. **U.S. Department of Health and Human Services.** *The Health Benefits of Smoking Cessation.* U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 1990.
53. **Mullen PD, Ramirez G, Groff JY.** A meta-analysis of randomized trials of prenatal smoking cessation interventions. *Am J Obstet Gynecol.* 1994;171:1328-34.

- *54. **Jorenby DE, Leischow SJ, Nides MA, et al.** A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. *N Engl J Med.* 1999;340:685-91.
- *55. **Chan B, Einarson A, Koren G.** Effectiveness of bupropion for smoking cessation during pregnancy. *J Addict Dis.* 2005; 24:19-23.
56. **Abel EL, Sokol RJ.** Incidence of fetal alcohol syndrome and economic impact of FAS-related anomalies. *Drug Alcohol Depend.* 1987;19:51-70.
57. **Hansom JW, Streissguth AP, Smith DW.** The effects of moderate alcohol consumption during pregnancy on fetal growth and morphogenesis. *J Pediatr.* 1978;92:457-60.
58. **Autti-Ramo I, Gaily E, Granstrom ML.** Dysmorphic features in offspring of alcoholic mothers. *Arch Dis Child.* 1992;67:712-16.
- *59. **Ernhart CB, Sokol RJ, Martier S, et al.** Alcohol teratogenicity in the human: a detailed assessment of specificity, critical period, and threshold. *Am J Obstet Gynecol.* 1987;156:33-9.
60. **Vega WA, Kolody B, Hwang J, Noble A.** Prevalence and magnitude of perinatal substance exposures in California. *N Engl J Med.* 1993;329:859-4.
61. **Shutzman DL.** Incidence of intrauterine cocaine exposure in a suburban setting. *Pediatrics.* 1991;88:825-7.
- *62. **Ness FB, Grisso JA, Hirshinger N, et al.** Cocaine and tobacco use and the risk of spontaneous abortion. *N Engl J Med.* 1999; 340: 333-86.
63. **MacGregor SN, Keith LG, Bachicha JA, Chasnoff IJ.** Cocaine abuse during pregnancy: correlation between prenatal care and perinatal outcome. *Obstet Gynecol.* 1989;74:882-5.
64. **Fricke HS, Segal S.** Narcotic addiction, pregnancy, and the newborn. *Am J Dis Child.* 1978;132:360-6.
65. **Gabbe SG, Turner LP.** Reproductive hazards of the American lifestyle: work during pregnancy. *Am J Obstet Gynecol.* 1997;176:826-32.
66. **Khattak S.** Pregnancy outcome following gestational exposure to organic solvents: a prospective controlled study. *JAMA.* 1999;281:1106-9.
67. **Schnorr TM, Grajewski BA, Hornung RW, et al.** Video display terminals and the risk of spontaneous abortion. *N Engl J Med.* 1991;324:727-33.
68. **Selevan SG, Lindbohm M-L, Hornung RW, Hemminki K.** A study of occupational exposure to antineoplastic drugs and fetal loss in nurses. *N Engl J Med.* 1985;313: 1173-8.

69. **Cohen E, Brown B, Bruce DL, et al.** Occupational disease among operating room personnel: a national study. *Anesthesiol.* 1974;41:321-40.
70. **Milunsky A, Ulcickas M, Rothman KJ, et al.** Maternal heat exposure and neural tube defects. *JAMA.* 1992;268:882-5.
71. **Offenbacher S, Katz V, Fertik G, et al.** Periodontal infection as a possible risk factor for preterm low birth weight. *J Periodontol.* 1996;67S:1103-13.
- *72. **Czeizel AE, Dudas I.** Prevention of the first occurrence of neural tube defects by periconceptional vitamin supplementation. *N Engl J Med.* 1992;327:1832-35.
- *73. **MRC Vitamin Study Research Group.** Prevention of neural tube defects: results of the medical research council vitamin study. *Lancet.* 1991;338:1027-31. *A seminal study demonstrating the efficacy of folic acid supplementation in the preconception and early pregnancy in preventing neural tube defects. The multi-center, randomized, double-blind trial was conducted in 7 countries and involved over 1800 women at risk for giving birth to infants with neural tube defects (based on prior pregnancies). Its definitive results led to important public health initiatives aimed at preventing neural tube defects.*
74. **Daly S, Mills JL, Molloy AM, et al.** Minimum effective dose of folic acid for food fortification to prevent neural-tube defects. *Lancet.* 1997;350:1666-9.
75. **Knowledge and use of folic acid by women of childbearing age.** *MMWR.* 1997;46:721.
76. **Rothman KJ, Moore LL, Singer MR, et al.** Teratogenicity of high vitamin A intake. *N Engl J Med.* 1995;333:1369-73, 1414-5.
- *77. **Goldenberg RL, Tamura T, Neggers Y, et al.** The effect of zinc supplementation on pregnancy outcome. *JAMA.* 1995;274:463-8.
- *78 **Werler MM, Louik C, Shapiro S, Mitchell AA. Prepregnant weight in relation to risk of neural tube defects.** *JAMA.* 1996; 275:1089-92.
79. **Shaw GM, Velie EM, Schaffer D.** Risk of neural tube defect-affected pregnancies among obese women. *JAMA.* 1996;275:1093-6.
80. **Schwartz D, Mayaux MJ.** Female fecundity as a function of age. *N Engl J Med.* 1982; 306:404-6.
- *81. **Cnattingius S, Forman MR, Berendes HW, Isotalo L.** Delayed childbearing and risk of adverse perinatal outcome. *JAMA.* 1992;268:886-90.
82. **Fretts RC, Schmittdiel J, McLean FH, et al.** Increased maternal age and the risk of fetal death. *N Engl J Med.* 1995;333:953-7.